Distinct Responsiveness to Intravitreal Ranibizumab Therapy in Polypoidal Choroidal Vasculopathy With Single or Multiple Polyps

We would like to thank Drs Uzun and Pehlivan for their interest in our recent study, which demonstrates the different responses to intravitreal 0.5 mg ranibizumab (IVR) therapy in 2 groups with treatment-naïve polypoidal choroidal vasculopathy (PCV), a subtype of age-related macular degeneration (AMD). The groups were classified according to the presence of single or multiple polyps.1 Although the baseline central retinal thickness (CRT) was almost the same between the groups, and both groups showed reduction in CRT after IVR, the single-polyp group showed significantly thinner CRT compared with the multiple-polyps group, 1 year after the initial IVR treatment.

Source: American Journal of Ophthalmology - July 13, 2016 Category: Opthalmology Authors: Misa Suzuki, Norihiro Nagai, Hajime Shinoda, Atsuro Uchida, Toshihide Kurihara, Yohei Tomita, Mamoru Kamoshita, Chigusa Iyama, Kazuo Tsubota, Yoko Ozawa Tags: Correspondence Source Type: research